Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:05 PM ET 8-K
Capital Raise Blue Owl Credit Income Corp. OCIC

Blue Owl Credit Income Capital Raise of $4.26M

Blue Owl Credit Income Corp. sold 464,303 unregistered shares of Class I common stock for approximately $4.26 million in a private offering to feeder vehicles. The company also reported that its continuous public offering has raised over $22.49 billion in total consideration to date across all share classes.

Value
$4.26M
4:03 PM ET 8-K
Divestiture 1 800 Flowers Com Inc FLWS

1 800 Flowers Com Divestiture to PlanetArt, LLC for $45M

1-800-FLOWERS.COM completed the sale of its Personalization Businesses, including Personalization Mall, Things Remembered, and Personalization Universe, to PlanetArt, LLC for $45.0 million in cash. The company used a portion of the net proceeds to prepay outstanding term loans under its existing credit facility.

Value
$45M
Counterparty
PlanetArt, LLC
4:03 PM ET 8-K
Capital Raise Blackstone Private Real Estate Credit & Income Fund

Blackstone Private Real Estate Credit & Income Fund Capital Raise of $2.73M

Blackstone Private Real Estate Credit and Income Fund sold 104,054 unregistered common shares of beneficial interest to investors in a private placement. The transaction, finalized on October 21, 2026, raised approximately $2.73 million in gross proceeds. The offering was conducted under exemptions from registration provided by Section 4(a)(2) and Regulation D/S of the Securities Act.

Value
$2.73M
4:00 PM ET 8-K
Capital Raise EQT Infrastructure Co LLC

EQT Infrastructure Co Capital Raise of $92.1M

EQT Infrastructure Company LLC sold 3,147,858 unregistered shares to third-party investors for aggregate cash consideration of approximately $92.1 million. The shares were sold at a price equal to the transactional net asset value per share as part of the company's continuous private offering, which has raised over $1.1 billion since inception in February 2026.

Value
$92.1M
4:00 PM ET 8-K
Capital Raise EQT Private Equity Co LLC

EQT Private Equity Co Capital Raise of $19.1M

EQT Private Equity Company LLC sold 663,060 unregistered shares to third-party investors for aggregate cash consideration of approximately $19.1 million. The shares were sold across multiple classes (Class I, J1, J2, and S) at prices based on the company's Transactional Net Asset Value per share. Since its inception in July 2025, the company has raised approximately $880.2 million through its continuous private offering.

Value
$19.1M
3:28 PM ET 8-K
Capital Raise Zevia PBC ZVIA

Zevia PBC Capital Raise of $15M

Zevia PBC entered into a securities purchase agreement with Bubble Holdings, LLC (an affiliate of GP Investments, Ltd.) to raise up to $20 million through the issuance of Series A Senior Convertible Preferred Stock. The company completed an initial closing of $15 million on October 22, 2026, with a deferred closing of $5 million contingent on meeting specific 2026 net sales and Adjusted EBITDA targets.

Value
$15M
Counterparty
Bubble Holdings, LLC

“This growth equity investment marks an important milestone in Zevia’s evolution and provides the capital, strategic resources, and operational expertise to accelerate our medium- and long-term growth agenda.”

Alexandre Ruberti, Zevia’s Chief Executive Officer

“We are thrilled to partner with Zevia and help support accelerated profitable growth. The team’s execution strengths and clear growth plan give us confidence in Zevia’s potential to become a leading everyday alternative to traditional soda, as consumers increasingly seek healthier options without artificial sweeteners.”

Rodrigo Boscolo, CEO of GP Investments
1:42 PM ET 8-K
Clinical Trial Data Ionis Pharmaceuticals Inc IONS

Ionis Pharmaceuticals Clinical Trial Data

Ionis Pharmaceuticals and its partner Roche announced positive Phase 3 IMAgINATION study results for sefaxersen in patients with IgA nephropathy. The trial met its primary endpoint, demonstrating a statistically significant 43.1% reduction in proteinuria compared to placebo at 37 weeks, with a safety profile consistent with earlier studies.

Counterparty
Roche

“These data support our belief that sefaxersen is uniquely positioned to treat IgA nephropathy, demonstrating significant and clinically meaningful reduction in proteinuria and offering the potential to help reduce the need for long-term dialysis or kidney transplantation.”

Brett P. Monia, Ph.D., chief executive officer, Ionis

“Sefaxersen is a powerful example of the broad impact of Ionis' innovative science, and based on these positive data, we believe it has the potential to be an important new treatment option for people living with IgA nephropathy.”

Brett P. Monia, Ph.D., chief executive officer, Ionis
12:53 PM ET 8-K
Capital Raise Lord Abbett Private Credit Fund

Lord Abbett Private Credit Fund Capital Raise of $34.1M

Lord Abbett Private Credit Fund issued and sold approximately 1.37 million common shares for aggregate proceeds of $34.1 million. The private placement was conducted at a price of $24.86 per share and was exempt from registration under Section 4(a)(2) and Regulation D. The fund also provided a portfolio update showing $2.36 billion in total loan commitments across 70 portfolio companies.

Value
$34.1M
12:04 PM ET 8-K
Nasdaq/NYSE Compliance Notice T3 Defense Inc. DFNS

T3 Defense Nasdaq/NYSE Compliance Notice

T3 Defense Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement of $10 million. The company resolved a previous deficiency caused by the non-cash liability classification of warrants, which had temporarily driven stockholders' equity into a deficit. Following the exercise of 96% of those warrants, the company reported pro forma stockholders' equity of approximately $99.9 million as of September 30, 2026.

Counterparty
Nasdaq
11:56 AM ET 8-K
M&A Deal Worthington Steel, Inc. WS

Worthington Steel M&A Deal with Kloeckner & Co SE

Worthington Steel provided a status update on its acquisition of Kloeckner & Co SE, noting that a proposed domination and profit and loss transfer agreement (DPLTA) failed to receive required shareholder approval. Despite the vote, Worthington Steel remains the majority owner with a 62% stake and will continue to consolidate Kloeckner's financial results while pursuing synergies under the existing governance structure.

Counterparty
Kloeckner & Co SE
11:45 AM ET 8-K
Capital Raise Vista Credit Strategic Lending Corp.

Vista Credit Strategic Lending Capital Raise of $7.23M

Vista Credit Strategic Lending Corp. sold 371,804.601 shares of its Class I common stock for total consideration of approximately $7.23 million. The unregistered sale was conducted via subscription agreements with accredited investors and non-U.S. persons. The company also reported a preliminary net asset value (NAV) per share of $19.44 as of September 30, 2026.

Value
$7.23M
11:31 AM ET 8-K
M&A Deal Bancfirst Corp BANF

Bancfirst M&A Deal with Spirit BankCorp, Inc.

BancFirst Corporation completed the acquisition of Spirit BankCorp, Inc. and its subsidiary SpiritBank, a privately held community bank headquartered in Tulsa, Oklahoma. SpiritBank, which has approximately $866.8 million in total assets and $776.4 million in deposits, was merged into BancFirst upon the closing of the transaction.

Counterparty
Spirit BankCorp, Inc.
11:16 AM ET 8-K
Capital Raise AB Private Credit Investors Corp

AB Private Credit Investors Capital Raise of $16.7M

AB Private Credit Investors Corp delivered a capital call notice to its investors for an aggregate offering price of approximately $16.69 million. The sale of common stock is being conducted under existing subscription agreements where investors fund capital commitments on an as-needed basis, with the closing expected around November 2, 2026.

Value
$16.7M
10:54 AM ET 8-K
Clinical Trial Data Perspective Therapeutics, Inc. CATX

Perspective Therapeutics Clinical Trial Data

Perspective Therapeutics announced updated interim Phase 1/2a results for [212Pb]VMT-α-NET in patients with SSTR2-expressing neuroendocrine tumors, showing objective response rates of 33% and 50% in Cohorts 2 and 3, respectively. The data demonstrated a 72% progression-free survival rate at 18 months with no dose-limiting toxicities, supporting the company's plan to initiate Phase 3 trials in 2027.

10:32 AM ET 8-K
M&A Deal Bolt Biotherapeutics, Inc. BOLT

Bolt Biotherapeutics M&A Deal with Prana Therapies, Inc.

Bolt Biotherapeutics acquired Prana Therapies in a stock-for-stock reverse merger, issuing common and Series D preferred stock to Prana shareholders. Following the merger and a concurrent $120 million private placement, former Prana equityholders will own approximately 51.7% of the combined company. The transaction shifts Bolt's focus to Prana's INSPIRE platform and its lead bispecific antibody candidate, PRA-216, for inflammatory diseases.

Counterparty
Prana Therapies, Inc.
10:00 AM ET 8-K
Capital Raise ExchangeRight Income Fund

ExchangeRight Income Fund Capital Raise

ExchangeRight Income Fund sold 16,740 Class D Common Shares for gross proceeds of $462,000 between October 8 and October 21, 2026. The sale is part of an ongoing continuous private placement offering of up to $2.165 billion in common shares.

9:15 AM ET 8-K
Clinical Trial Data Eikon Therapeutics, Inc. EIKN

Eikon Therapeutics Clinical Trial Data

Eikon Therapeutics presented initial and updated Phase 1/2 clinical data for its PARP1-selective inhibitors (EIK1003, EIK1004) and WRN helicase inhibitor (EIK1005) at the 2026 ESMO Congress. EIK1003 monotherapy showed a 31.3% objective response rate in PARP-naïve patients with HRR-mutated tumors, while EIK1004 and EIK1005 demonstrated favorable safety and tolerability profiles in early dose-escalation cohorts.

“These data strengthen the foundation of our clinical-stage pipeline, with encouraging evidence of activity and tolerability across our selective PARP1 programs. The EIK1003 results support continued development both as monotherapy and in combination with established cancer treatments, while the initial EIK1004 findings support further evaluation of our CNS-penetrant PARP1 inhibitor. The first clinical results for EIK1005, our internally derived WRN helicase inhibitor, mark an important step in translating Eikon’s discovery science into potential new medicines for patients.”

Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon
9:03 AM ET 8-K
M&A Deal Arcosa, Inc. ACA

Arcosa M&A Deal with CRH Americas, Inc.

Arcosa, Inc. completed its merger with CRH Americas, Inc., a subsidiary of CRH plc, resulting in Arcosa becoming a wholly owned subsidiary of CRH. Under the terms of the agreement, Arcosa stockholders received $150.00 in cash for each share of common stock held. In connection with the closing, Arcosa terminated its $1.4 billion senior secured credit facility and repaid approximately $450.1 million in outstanding obligations.

Counterparty
CRH Americas, Inc.
9:01 AM ET 8-K
Licensing Deal Tempus AI, Inc. TEM

Tempus AI Licensing Deal with Bristol-Myers Squibb Company Worth $192M

Tempus AI entered into a series of agreements with Bristol-Myers Squibb (BMS) and Pathos AI to expand the use of its de-identified multimodal real-world data and analysis tools. The deal provides for aggregate cash payments to Tempus of $192.5 million over approximately five years, including $137.5 million for oncology data services to BMS and $55 million for neurology data and agentic tools to Pathos to support BMS's therapeutic development.

Value
$192M
Counterparty
Bristol-Myers Squibb Company
Term
5 years
8:52 AM ET 8-K
M&A Deal Crh Public Ltd Co CRH

Crh Public Ltd Signs $8.5B M&A Deal with Arcosa, Inc.

CRH completed its acquisition of Arcosa, Inc., a leading U.S. provider of aggregates and critical infrastructure products, for an enterprise value of approximately $8.5 billion. The deal reinforces CRH's position as the top infrastructure player in North America and increases its exposure to major road, water, energy, and data projects.

Value
$8.5B
Counterparty
Arcosa, Inc.

“Arcosa is an excellent strategic fit for CRH and fully aligns with our growth ambitions. With high-quality aggregates assets and attractive positions in the growing U.S. energy transmission market, the acquisition strengthens our connected portfolio and reinforces our position as the #1 infrastructure player in North America. We look forward to welcoming our Arcosa colleagues into CRH and executing on the strong growth opportunities ahead.”

Jim Mintern, CRH CEO
8:41 AM ET 8-K
Clinical Trial Data Aardvark Therapeutics, Inc. AARD

Aardvark Therapeutics Clinical Trial Data

Aardvark Therapeutics reported exploratory efficacy data from its terminated Phase 3 HERO and open-label extension trials for ARD-101 in Prader-Willi syndrome. The data showed reductions in hunger scores (HQ-CT) during treatment that returned to baseline upon discontinuation, and the FDA has lifted a full clinical hold on the program. The company plans to meet with the FDA to align on a new Phase 3 trial design using a lower dose, with clinical activities expected to resume in 2027.

8:31 AM ET 8-K
M&A Deal Nordson Corp NDSN

Nordson Signs $168M M&A Deal with Contrinex Holding SA

Nordson Corporation, through its subsidiary Nordson London Limited, completed the acquisition of Switzerland-based Contrinex Holding SA for an enterprise value of approximately $168 million. Contrinex is a global leader in high-performance sensors for factory automation, generating approximately $50 million in annual revenue, and will be integrated into Nordson’s Advanced Technology Solutions segment.

Value
$168M
Counterparty
Contrinex Holding SA
8:03 AM ET 8-K
Capital Raise TPG Private Equity Opportunities, L.P.

TPG Private Equity Opportunities Capital Raise of $73.1M

TPG Private Equity Opportunities, L.P. raised $73.1 million in aggregate consideration through the sale of unregistered limited partnership units on October 1, 2026. The sale was part of the Fund's continuous private offering and included Class I, Class S, and Class F units. The broader T-POP Fund Complex issued interests totaling approximately $103.2 million during the same period.

Value
$73.1M
8:01 AM ET 8-K
Clinical Trial Data Oric Pharmaceuticals, Inc. ORIC

Oric Pharmaceuticals Clinical Trial Data

ORIC Pharmaceuticals reported updated Phase 1b data for enozertinib (ORIC-114) in patients with EGFR-mutant non-small cell lung cancer, showing an 84% confirmed systemic objective response rate. The data, presented at the ESMO Congress 2026, also highlighted significant intracranial activity and plans to initiate a global Phase 3 registrational trial in the first half of 2027.

7:31 AM ET 8-K
M&A Deal Intelligent Protection Management Corp. IPM

Intelligent Protection Management Signs $2.7M M&A Deal with Advanced Technology Distributors Inc.

Intelligent Protection Management Corp. (IPM) has entered into a definitive agreement to acquire the managed services business of Advanced Technology Distributors Inc. (AdTech) for up to $2.7 million. The transaction is structured in two stages, with IPM initially acquiring a 49% stake in a newly formed subsidiary (JVCo) followed by the remaining 51% upon receiving regulatory approvals from the California Public Utilities Commission. The deal aims to expand IPM's managed technology solutions and cybersecurity capabilities into the California market.

Value
$2.7M
Counterparty
Advanced Technology Distributors Inc.
6:36 AM ET 8-K
Clinical Trial Data Tango Therapeutics, Inc. TNGX

Tango Therapeutics Clinical Trial Data

Tango Therapeutics announced updated Phase 1/2 clinical trial results for vopimetostat in combination with daraxonrasib, showing an 82% objective response rate in patients with MTAP-deleted and RAS-mutant pancreatic cancer. The data demonstrated a 9-month progression-free survival rate of 88%, leading the company to plan a registrational Phase 3 trial in the first half of 2027.

Counterparty
Revolution Medicines, Inc.
6:32 AM ET 8-K
M&A Deal Ftai Infrastructure Inc. FIP

Ftai Infrastructure Signs $255M M&A Deal with DRUbit LLC

FTAI Infrastructure's subsidiary Jefferson is providing a status update on its $255 million acquisition of DRUbit LLC from US Development Group. Jefferson plans to incur $270 million in new debt to fund the deal and expects the acquired assets to contribute $50 million in annual Adjusted EBITDA, effectively doubling Jefferson's total annual Adjusted EBITDA to approximately $100 million.

Value
$255M
Counterparty
DRUbit LLC
Term
through July 2031
6:07 AM ET 8-K
Licensing Deal Zymeworks Inc. ZYME

Zymeworks Licensing Deal with Roche Worth $813M

Zymeworks entered into a global collaboration and license agreement with Roche for the development and commercialization of ZW209, a trispecific T-cell engager targeting DLL3. Zymeworks will receive a $55 million upfront payment and a $40 million milestone upon Phase 1b trial initiation, with eligibility for up to $718 million in additional milestones plus tiered royalties.

Value
$813M
Counterparty
Roche
6:07 AM ET 8-K
Capital Raise Zai Lab Ltd ZLAB

Zai Lab Capital Raise of $250M

Zai Lab Limited entered into a securities purchase agreement with accredited investors for a private placement (PIPE) of 11,340,000 American depositary shares (ADSs). The company expects to receive gross proceeds of approximately $250 million to fund pipeline development and general corporate purposes. The ADSs are priced at $22.04 each, and the company has agreed to file a registration statement for the resale of these securities.

Value
$250M
6:05 AM ET 8-K
Divestiture S&P Global Inc. SPGI

S&P Global Divestiture

S&P Global Inc. provided pro forma financial statements following the completed spin-off of its S&P Global Mobility segment into an independent public company, Mobility Global Inc. (NYSE: MBGL). The separation was executed via a pro rata distribution of one share of Mobility Global for every share of S&P Global held as of the June 15, 2026 record date.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.